Park, C.S.; Sung, M.J.; Kim, S.J.; Jo, J.H.; Lee, H.S.; Chung, M.J.; Bang, S.; Park, S.W.; Song, S.Y.; Park, J.Y.
Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer. Cancers 2022, 14, 4323.
https://doi.org/10.3390/cancers14174323
AMA Style
Park CS, Sung MJ, Kim SJ, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY.
Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer. Cancers. 2022; 14(17):4323.
https://doi.org/10.3390/cancers14174323
Chicago/Turabian Style
Park, Chan Su, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, and Jeong Youp Park.
2022. "Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer" Cancers 14, no. 17: 4323.
https://doi.org/10.3390/cancers14174323
APA Style
Park, C. S., Sung, M. J., Kim, S. J., Jo, J. H., Lee, H. S., Chung, M. J., Bang, S., Park, S. W., Song, S. Y., & Park, J. Y.
(2022). Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer. Cancers, 14(17), 4323.
https://doi.org/10.3390/cancers14174323